Novavax raised its full-year adjusted revenue forecast on Wednesday, banking on higher sales tied to its vaccine supply partnerships, including with South Korea's SK Bioscience and Japan's Takeda.

The federal government is calling off around $500 million worth of vaccine development projects that use mRNA technology, ...